CDKN2A and melanoma: Using this strategy, we were able to characterize in-depth predominant melanoma drivers—BRAF, NRAS, PTEN, TP53, CDKN2A—and also validate recently identified melanoma genes, RAC1(p.P29S)9, 10 and STK19(p.D89N)9.